Tags

Type your tag names separated by a space and hit enter

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT.
Haematologica. 2020; 105(2):414-423.H

Abstract

Deletion 5q or monosomy 5 (-5/5q-) in acute myeloid leukemia (AML) is a common high-risk feature that is referred to allogeneic stem cell transplantation. However, -5/5q- is frequently associated with other high-risk cytogenetic aberrations such as complex karyotype, monosomal karyotype, monosomy 7 (-7), or 17p abnormalities (abn (17p)), the significance of which is unknown. In order to address this question, we studied adult patients with AML harboring -5/5q- having their first allogeneic transplantation between 2000 and 2015. Five hundred and one patients with -5/5q- have been analyzed. Three hundred and thirty-eight patients (67%) were in first remission and 142 (28%) had an active disease at time of allogeneic transplantation. The 2-year probabilities of overall survival and leukemia-free survival were 27% and 20%, respectively. The 2-year probability of treatment-related mortality was 20%. We identified four different cytogenetic groups according to additional abnormalities with prognostic impact: -5/5q- without complex karyotype, monosomal karyotype or abn(17p), -5/5q- within a complex karyotype, -5/5q- within a monosomal karyotype and the combination of -5/5q- with abn(17p). In multivariate analysis, factors associated with worse overall survival and leukemia-free survival across the four groups were active disease, age, monosomal karyotype, and abn(17p). The presence of -5/5q- without monosomal karyotype or abn(17p) was associated with a significantly better survival rate while -5/5q- in conjunction with monosomal karyotype or abn(17p) translated into a worse outcome. The patients harboring the combination of -5/5q- with abn(17p) showed very limited benefit from allogeneic transplantation.

Authors+Show Affiliations

Section of Hematology, Cliniques Universitaires St-Luc, Brussels, Belgium xavier.poire@uclouvain.be.Acute Leukemia Working Party of the EBMT. Sorbonne Université, Paris, France. INSERM UMR 938, Paris, France. Service d'Hématologie, Hôpital Saint-Antoine, Paris, France.Acute Leukemia Working Party of the EBMT. Sorbonne Université, Paris, France. INSERM UMR 938, Paris, France. Service d'Hématologie, Hôpital Saint-Antoine, Paris, France.CHU Bordeaux, Hôpital Haut-Leveque, Pessac, France.Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland.Service d'Hématologie, Centre Hospitalier Lyon Sud, Lyon, France.Institut Paoli Calmette, Programme de Transplantation Thérapie Cellulaire, Marseille, France.CHU de Lille, LIRIC INSERM U995, Université Lille2, Lille, France.University Hospital Gasthuisberg, Leuven, Belgium.Servicio de Hematologica-Hemoterapia, Hospital U. Marquès de Valdecilla, Santander, Spain.Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.Department of Medicine-Hematology-Oncology, University of Freiburg, Freiburg, Germany.Acute Leukemia Working Party of the EBMT. Sorbonne Université, Paris, France. INSERM UMR 938, Paris, France. Service d'Hématologie, Hôpital Saint-Antoine, Paris, France.Hematology Department, Hospital Clinic, Barcelona, Spain.Acute Leukemia Working Party of the EBMT. Sorbonne Université, Paris, France. Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31048355

Citation

Poiré, Xavier, et al. "Allogeneic Stem Cell Transplantation Using HLA-matched Donors for Acute Myeloid Leukemia With Deletion 5q or Monosomy 5: a Study From the Acute Leukemia Working Party of the EBMT." Haematologica, vol. 105, no. 2, 2020, pp. 414-423.
Poiré X, Labopin M, Polge E, et al. Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. Haematologica. 2020;105(2):414-423.
Poiré, X., Labopin, M., Polge, E., Forcade, E., Ganser, A., Volin, L., Michallet, M., Blaise, D., Yakoub-Agha, I., Maertens, J., Espiga, C. R., Cornelissen, J., Finke, J., Mohty, M., Esteve, J., & Nagler, A. (2020). Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. Haematologica, 105(2), 414-423. https://doi.org/10.3324/haematol.2019.216168
Poiré X, et al. Allogeneic Stem Cell Transplantation Using HLA-matched Donors for Acute Myeloid Leukemia With Deletion 5q or Monosomy 5: a Study From the Acute Leukemia Working Party of the EBMT. Haematologica. 2020;105(2):414-423. PubMed PMID: 31048355.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. AU - Poiré,Xavier, AU - Labopin,Myriam, AU - Polge,Emmanuelle, AU - Forcade,Edouard, AU - Ganser,Arnold, AU - Volin,Liisa, AU - Michallet,Mauricette, AU - Blaise,Didier, AU - Yakoub-Agha,Ibrahim, AU - Maertens,Johan, AU - Espiga,Carlos Richard, AU - Cornelissen,Jan, AU - Finke,Jürgen, AU - Mohty,Mohamad, AU - Esteve,Jordi, AU - Nagler,Arnon, Y1 - 2020/01/31/ PY - 2019/01/07/received PY - 2019/04/24/accepted PY - 2019/5/3/pubmed PY - 2021/4/28/medline PY - 2019/5/4/entrez SP - 414 EP - 423 JF - Haematologica JO - Haematologica VL - 105 IS - 2 N2 - Deletion 5q or monosomy 5 (-5/5q-) in acute myeloid leukemia (AML) is a common high-risk feature that is referred to allogeneic stem cell transplantation. However, -5/5q- is frequently associated with other high-risk cytogenetic aberrations such as complex karyotype, monosomal karyotype, monosomy 7 (-7), or 17p abnormalities (abn (17p)), the significance of which is unknown. In order to address this question, we studied adult patients with AML harboring -5/5q- having their first allogeneic transplantation between 2000 and 2015. Five hundred and one patients with -5/5q- have been analyzed. Three hundred and thirty-eight patients (67%) were in first remission and 142 (28%) had an active disease at time of allogeneic transplantation. The 2-year probabilities of overall survival and leukemia-free survival were 27% and 20%, respectively. The 2-year probability of treatment-related mortality was 20%. We identified four different cytogenetic groups according to additional abnormalities with prognostic impact: -5/5q- without complex karyotype, monosomal karyotype or abn(17p), -5/5q- within a complex karyotype, -5/5q- within a monosomal karyotype and the combination of -5/5q- with abn(17p). In multivariate analysis, factors associated with worse overall survival and leukemia-free survival across the four groups were active disease, age, monosomal karyotype, and abn(17p). The presence of -5/5q- without monosomal karyotype or abn(17p) was associated with a significantly better survival rate while -5/5q- in conjunction with monosomal karyotype or abn(17p) translated into a worse outcome. The patients harboring the combination of -5/5q- with abn(17p) showed very limited benefit from allogeneic transplantation. SN - 1592-8721 UR - https://www.unboundmedicine.com/medline/citation/31048355/Allogeneic_stem_cell_transplantation_using_HLA_matched_donors_for_acute_myeloid_leukemia_with_deletion_5q_or_monosomy_5:_a_study_from_the_Acute_Leukemia_Working_Party_of_the_EBMT_ L2 - https://doi.org/10.3324/haematol.2019.216168 DB - PRIME DP - Unbound Medicine ER -